Tag: anastrozole
Articles
- Breast cancer patients who gain weight after diagnosis have worse prognosis
- What should breast cancer survivors eat during aromatase inhibitor treatment?
News
- Aromatase inhibitor only or after tamoxifen are both effective treatments
- Aromatase inhibitors can increase risk of early hip fracture in breast cancer survivors
- Aromatase inhibitors can worsen cholesterol profile
- Aromatase inhibitors can worsen sexual function after breast cancer
- Bisphosphonate Zometa might increase survival in certain premenopausal breast cancer cases
- High dose vitamin D reduces musculoskeletal symptoms in women taking Arimidex
- Increasingly severe side effects of aromatase inhibitors may make tamoxifen first the best strategy
- Switch in aromatase inhibitors can enable some with breast cancer to continue AI treatment
- Tamoxifen treatment results in cognitive impairment compared to Aromasin
- Treatment with aromatase inhibitors results in better breast cancer outcomes than tamoxifen
- Weight gain can increase hot flashes in breast cancer survivors on aromatase inhibitors
Studies
- Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer
- Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer
- Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study
- Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole
- Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial
- Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole
- Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor-Positive Breast Cancer in Postmenopausal Women
- Short-Term Biomarker Modulation Prevention Study of Anastrozole in Women at Increased Risk for Second Primary Breast Cancer
- Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group
- The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
- Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial
- Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer